Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Rhythm Pharmaceuticals amended its exclusive license agreement with LG Chem for Bivamelagon, including $350M in fixed payments over 4 years and a 1% royalty. The company also secured a $750M term loan from KKR and Blackstone at SOFR+4.60%.
How this was made
The 30-second read
Why it matters
The amendment secures a substantial financing package and guarantees future revenue, likely improving Rhythm's balance sheet and funding pipeline.
Market read
The deal adds significant cash flow and financing to Rhythm, a material event for investors tracking biotech financing trends.
What to watch
The terms of the amendment may include performance milestones that, if unmet, could trigger penalties.
Background
Rhythm Pharmaceuticals (RYTM) is a US‑listed biotech focused on rare disease therapeutics. LG Chem is a major Korean chemical and pharma company.
Ticker impact
Rhythm Pharmaceuticals amended its exclusive license with LG Chem, adding $350M fixed payments over four years and secured a $750M term loan.
potential upside as the market prices in the new financing and revenue stream
Large fixed payments and a sizable loan reduce financing risk and signal confidence from major investors, which typically lifts share price.
Market effects
Strengthens the biotech licensing landscape, showing increased partnership activity with large chemical firms.
May boost investor sentiment toward US biotech firms engaging in strategic Asian partnerships.
Highlights cross‑border collaboration in drug development, modestly relevant to global pharma investors.
Counterpoint
The fixed royalty and loan could increase Rhythm's debt burden, potentially limiting future flexibility.
Key entities
- CompanyRhythm Pharmaceuticals
US biotech firm receiving the license amendment and loan.
- CompanyLG Chem
Korean chemical and pharma partner providing the license.
